Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ATR | Q13535 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889406 | 0.82 | MCHR1 (0.73) | ATRMCHR1 | |
| SCHEMBL2886450 | 0.75 | MCHR1 (0.58) | ALDH1A1SMN1; SMN2ATRMCHR1 | |
| SCHEMBL12585052 | 0.75 | MAPK1 (0.79) | GHSRKDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL2885651 | 0.74 | ATR (0.57) | KDM4ESMN1; SMN2ATRMCHR1 | |
| SCHEMBL13501815 | 0.74 | ALDH1A1 (0.84) | GHSRKDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL10293598 | 0.73 | L3MBTL3 (0.69) | KDM4ESMN1; SMN2ATR | |
| SCHEMBL10293555 | 0.73 | L3MBTL3 (0.69) | KDM4ESMN1; SMN2ATR | |
| SCHEMBL2890112 | 0.73 | ATR (0.56) | ALDH1A1MAPK1SMN1; SMN2ATRMCHR1 | |
| SCHEMBL13501816 | 0.73 | GAA (0.74) | GHSRKDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL2885719 | 0.72 | ATR (0.55) | ATRMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH (US) | 2007-11-22 | — | — | US | claimed |
| US-7842715-B2 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH (US) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | HRH4, HRH3, HRH2 | GHSR 239/4885KDM4E 1644/4885ALDH1A1 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.